Improving immunotherapy response through the use of designer bacteria
- PMID: 34906317
- DOI: 10.1016/j.ccell.2021.11.009
Improving immunotherapy response through the use of designer bacteria
Abstract
Reprogramming the tumor microenvironment may be a key strategy to broaden the efficacy of current cancer immunotherapies. In a recent Nature paper, Canale et al. use synthetic biology to alter intratumoral arginine levels via engineered bacteria, leading to improved responsiveness to anti-PD-L1 checkpoint blockade in a murine model of cancer.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.E.G. and H.C.H. have filed a patent application (PCT/US2020/019038) for the commercial use of SagA bacteria to improve checkpoint blockade immunotherapy.
Comment on
-
Metabolic modulation of tumours with engineered bacteria for immunotherapy.Nature. 2021 Oct;598(7882):662-666. doi: 10.1038/s41586-021-04003-2. Epub 2021 Oct 6. Nature. 2021. PMID: 34616044
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials